Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
ZIOP - Ziopharm Oncology, Inc.
0.18(3.70%)9:00:00 PM 2/24/2021
ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells. It is developing Ad-RTS-hIL-12 plus veledimex, which is in Phase 2 clinical trial, to treat patients with recurrent glioblastoma multiforme in adults. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has license agreement with Precigen, Inc. and MD Anderson Cancer Center; collaboration with MD Anderson targeting CD19 on malignant B cells using Sleeping Beauty platform; and research and development agreement with the National Cancer Institute to evaluate autologous peripheral blood lymphocytes, and Ares Trading S.A. The company was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 


Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.


  • Volatility is at a recent 2 week low. A recent low volatility of stock movement within a box range could trigger break through when activities pick up.
  • A moving average of short volume ratio is at a recent 2 week low. A lower short volume ratio could be a bullish signal.
Stock Statistics
PE Ratio
PEG Ratio
P/S (ttm)
Earning Growth (QoQ)
Revenue Growth (QoQ)
Short %17%
Held by Institutions %55%
1 Day Vol Adjusted Return0.4
1 Month Vol Adjusted Return4.1
3 Month Vol Adjusted Return11.6
6 Month Vol Adjusted Return12.5
20 Days SMA Price ZScore0.3
50 Days SMA Price ZScore1.3
12 -26 Days PPO8.2
1 Month Average Short Volume Ratio54.5
1 Day Volume Change ZScore-1.0
1 Month Daily Vol8.4
Related Topics
leak data

Related Topics


Stock news

    Ziopharm Oncology to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast on February 25, 2021

    Company to Hold R&D Day on Thursday, March 11, 2021BOSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (the “Company”) (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast to discuss financial results for the fourth quarter and full year 2020 on Thursday, February 25, 2021 at 4:30pm EDT. The live call can be accessed by dialing 1-877-451-6152 (U.S. and Canada) or 1-201-389-0879 (International). The passcode for the conference call is 13715482. The liv...

    Analyzing ZIOPHARM Oncology's Unusual Options Activity

    Shares of ZIOPHARM Oncology (NASDAQ:ZIOP) saw some unusual options activity on Monday. Following the unusual option alert, the stock price moved up to $5.61. Sentiment: BULLISH Option Type: TRADE Trade Type: CALL Expiration Date: 2022-01-21 Strike Price: $7.00 Volume: 957 Open Interest: 4778 Three Ways Options Activity Is ‘Unusual' One way options market activity can be considered unusual is when volume is exceptionally higher than its historical average. The volume of options activity refers to...

    Why Ziopharm Oncology Stock Is Soaring Today

    Shares of Ziopharm Oncology (NASDAQ: ZIOP) were soaring 11.8% as of 11:45 a.m. EST on Friday. The nice gain came after the company announced the election of Robert Postma to its board of directors. The addition expanded Ziopharm's board from eight members to nine.

    Ziopharm Oncology Announces Election of Robert Postma to its Board of Directors

    BOSTON, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced the election of Robert Postma to its Board of Directors (the “Board”), effective immediately. Mr. Postma is the Founder of WaterMill Asset Management, a sizeable and long-term shareholder of Ziopharm. James Huang, Chairman of the Board, said, “We welcome Bob to Ziopharm’s Board of Directors. With his experience and financial acumen, Bob will make an immediate contribution...

    Ziopharm Oncology Announces Election of James Huang as Chairman of the Board of Directors

    – Mr. Huang is a veteran industry entrepreneur with 20+ years founding and funding biotech innovation – – Heidi Hagen elected Lead Independent Director –BOSTON, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP) today announced the election of James Huang as Chairman of the Board of Directors (the “Board”), effective immediately.Mr. Huang has served on the Board since July 2020 and is currently a Managing Partner at Kleiner Perkins Caufield & ...

    Ziopharm to Participate in Upcoming January Conferences

    BOSTON, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the H.C. Wainwright Bioconnect 2021 Conference and will deliver a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference. H.C. Wainwright Bioconnect 2021 Conference Date: Monday, January 11, 2021 Time: 6:00 am ET (access to on dem...